DeFrancesco C J, Flynn J M, Smith J T, Luhmann S J, Sawyer J R, Glotzbecker M, Pahys J, Garg S, Vitale M, Farrington D M, Sturm P
The Children's Hospital of Philadelphia, Division of Orthopaedics, 3401 Civic Center Blvd., Philadelphia, PA 19104, USA and The Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA, 3400 Civic Center Blvd, Philadelphia, PA 19104, USA.
The Children's Hospital of Philadelphia, Division of Orthopaedics, Philadelphia, PA, USA, 3401 Civic Center Blvd., Philadelphia, PA 19104, USA.
J Child Orthop. 2017 Dec 1;11(6):414-418. doi: 10.1302/1863-2548.11.170107.
Spine surgeons have increasingly used intraoperative application of topical vancomycin powder (TVP) to prevent surgical site infections (SSIs). The goals of this study were to define the rate of pharmacological adverse reaction to TVP in young patients undergoing posterior spinal surgery and to summarise institutional variation in TVP dosing.
This retrospective observational study included ten spine centres in the United States and one in Europe. Patients with early onset scoliosis who underwent posterior spine surgery were eligible for inclusion. Age, weight, TVP dose and surgery type were recorded. Surgeries where patient age was > 12 years were excluded. Pharmacological adverse reactions were defined as clinical instances of Red Man Syndrome, rash, nephrotoxicity, proteinuria, hepatotoxicity or ototoxicity. The rate of pharmacological adverse reaction to TVP was calculated. Dosing practices were summarised.
Patient age was in the range of seven months to 12 years (median ten years). Of 1398 observations, there was one possible pharmacological adverse reaction. This was in a ten-year-old, 20.4-kg female patient with neuromuscular sco-liosis undergoing growing rod implantation. She was dosed with 1500 mg of TVP and immediately developed a transient rash without systemic symptoms. This abated over minutes without any medical intervention. There were no other adverse reactions in the sample. The population rate of pharmacological adverse reaction was 0.072% (95% confidence interval 0 to 0.4). Significant variability in dosing practices existed between centres.
Pharmacological adverse reactions to TVP are rare. Future work may establish evidence-based guidelines for TVP dosing based on patient weight and other variables.
脊柱外科医生越来越多地在术中应用局部万古霉素粉末(TVP)以预防手术部位感染(SSI)。本研究的目的是确定接受后路脊柱手术的年轻患者中对TVP发生药物不良反应的发生率,并总结TVP给药的机构差异。
这项回顾性观察性研究纳入了美国的10个脊柱中心和欧洲的1个脊柱中心。接受后路脊柱手术的早发性脊柱侧弯患者符合纳入标准。记录患者的年龄、体重、TVP剂量和手术类型。排除患者年龄>12岁的手术。药物不良反应定义为红人综合征、皮疹、肾毒性、蛋白尿、肝毒性或耳毒性的临床实例。计算对TVP发生药物不良反应的发生率。总结给药方法。
患者年龄在7个月至12岁之间(中位年龄10岁)。在1398例观察中,有1例可能的药物不良反应。该病例为一名10岁、体重20.4 kg的女性神经肌肉型脊柱侧弯患者,在进行生长棒植入手术时使用了1500 mg TVP,随后立即出现短暂皮疹,但无全身症状。数分钟后皮疹消退,未进行任何医学干预。样本中无其他不良反应。药物不良反应的总体发生率为0.072%(95%置信区间为0至0.4)。各中心之间的给药方法存在显著差异。
TVP的药物不良反应很少见。未来的研究可能会根据患者体重和其他变量制定基于证据的TVP给药指南。